All In Biotech

Free tool

FAERS Monitor: Mycapssa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208232 or its brand name (Mycapssa, Octreotide Acetate). Reports on generic versions are filed under their own applications.

Reports

5,732

Serious

4,922

86% of reports

Hospitalization

2,370

Death reported

920

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use753
  • drug ineffective718
  • diarrhoea550
  • death393
  • nausea373
  • fatigue325
  • malignant neoplasm progression253
  • abdominal pain232
  • vomiting219
  • weight decreased187
  • dyspnoea186
  • drug ineffective for unapproved indication185
  • pain180
  • product use in unapproved indication179
  • asthenia169

Reports by year received

View as table
YearReports
20046
200523
20065
20073
20082
200910
20109
201116
201270
2013105
2014143
2015192
2016225
2017343
2018380
2019347
2020333
2021572
2022630
2023600
2024542
2025682
2026494

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,427 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug ineffective for unapproved indicationSignal18512.410.81,928
malignant neoplasm progressionSignal2539.18.11,817
abdominal painSignal2323.73.2451
off label useSignal7533.23.01,155
diarrhoeaSignal5503.12.9819
product use in unapproved indicationSignal1792.72.3185
weight decreasedSignal1872.52.1162
drug ineffective7182.01.9382
nausea3731.71.6118
vomiting2191.71.565
death3931.71.5110
asthenia1691.61.443
fatigue3251.51.462
dyspnoea1861.21.06
pain1801.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.